Loading
A phase 2 trial in triple-negative breast cancer, run by Affiliated Hospital of Nantong University, now recruiting.
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT07342283 by Affiliated Hospital of Nantong University, with a registry enrolment figure of 30 participants, started 2026-02-25 and due to reach its primary completion in 2027-12-25. Interventions recorded: Immunotherapy combined with chemotherapy. Conditions listed: Triple Negative Breast Cancer (TNBC). Sites: China. No results are recorded here; the registry entry is the source.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.